低剂量直接口服抗凝药用于反复静脉血栓栓塞事件史或严重血栓形成倾向高危复发患者的二级预防:意大利抗凝患者登记调查2的回顾性分析
该研究回顾性分析了意大利抗凝患者登记调查2中487例有反复静脉血栓栓塞事件史和/或严重血栓形成倾向的高危复发患者,记录其抗凝药物及剂量并随访不良事件。311例(63.9%)在中位1.3年后转为低剂量直接口服抗凝药,继续治疗者中复发率为0.4/100患者年、出血率为0.9/100患者年,全剂量与低剂量组复发风险相似,全剂量组出血风险有升高趋势(相对风险2.2,95%CI 0.7-9.0)。
要点
- 487例高危复发患者中63.9%转为低剂量直接口服抗凝药,其中阿哌沙班2.5 mg每日两次占61.4%,利伐沙班10 mg每日一次占38.6%。
- 继续抗凝治疗者复发率为0.4/100患者年,出血率为0.9/100患者年;停药者随访期间无不良事件记录。
- 全剂量与低剂量抗凝的复发风险相似,全剂量组出血风险有升高趋势(相对风险2.2,95%CI 0.7-9.0)。
核心结论
- 有自发性反复静脉血栓栓塞事件史和/或严重血栓形成倾向的高危复发患者长期接受低剂量直接口服抗凝药治疗,复发和出血事件风险均较低。
研究设计与样本
- 意大利抗凝患者登记调查2(Survey on anTicoagulated pAtients RegisTry 2)的回顾性分析,共纳入2520例静脉血栓栓塞患者,其中487例为有反复静脉血栓栓塞事件史和/或严重血栓形成倾向的高危复发患者。
主要发现
- 487例高危复发患者中,11例(2.3%)停止抗凝,176例(36.1%)继续全剂量直接口服抗凝药,311例(63.9%)在中位1.3年(范围0.5-20.2年)后转为低剂量直接口服抗凝药。
- 低剂量直接口服抗凝药中,61.4%使用阿哌沙班2.5 mg每日两次,38.6%使用利伐沙班10 mg每日一次。
- 停药患者随访期间未记录到不良事件;继续治疗患者中10例复发静脉血栓栓塞(发生率0.4/100患者年),19例出血(发生率0.9/100患者年)。
- 全剂量与低剂量抗凝患者复发静脉血栓栓塞风险相似;全剂量抗凝患者出血风险有升高趋势(相对风险2.2,95%CI 0.7-9.0)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term anticoagulation is recommended in patients with venous thromboembolism (VTE) deemed at high risk for recurrence (HRR). Limited information is available on patients with recurrent VTE and/or severe thrombophilia. In addition, these patients were not included in studies evaluating long-term treatment with low doses of direct oral anticoagulants (DOACs). OBJECTIVES: The aims of our study were to (1) record the drugs and dosages used in HRR patients, and (2) to record adverse events occurring during follow-up. METHODS: Among 2520 VTE patients enrolled in the Survey on anTicoagulated pAtients RegisTry 2, we retrospectively analyzed the management of patients with a history of recurrent VTE and/or severe thrombophilia (HRR patients). RESULTS: A total of 487 HRR patients were analyzed. Anticoagulants were stopped in 11 of 487 patients (2.3%), full-dose DOACs were continued in 176 patients (36.1%), and 311 patients (63.9%) were shifted to low-dose DOACs (61.4% with apixaban 2.5 mg twice a day and 38.6% with rivaroxaban 10 mg once a day) after a median time of 1.3 years (range, 0.5-20.2 years). During follow-up, no adverse events were recorded in patients who stopped treatment. Among patients who continued treatment, 10 had recurrent VTE (rate, 0.4 × 100 patient-years) and 19 had bleeding (rate, 0.9 × 100 patient-years). The risk of recurrent VTE was similar between patients on full-dose and low-dose anticoagulation. Patients on full-dose anticoagulation had a trend toward a higher bleeding risk (relative risk, 2.2; 95% CI, 0.7-9.0). CONCLUSION: HRR patients with a history of unprovoked recurrent VTE and/or patients with severe thrombophilia treated with long-term low-dose DOACs showed a low risk for recurrence and bleeding events.
引用
- Poli D, Parisi R, Antonucci E, et al. Low-dose direct oral anticoagulants for secondary prevention in patients at high risk for recurrence due to history of recurrent venous thromboembolic events or severe thrombophilia: a retrospective analysis of the Italian Survey on anTicoagulated pAtients RegisTry 2. J Thromb Haemost. 2025. PMID: 40803569. doi:10.1016/j.jtha.2025.07.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。